Replies to post #303310 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

I understand what you wanted to illustrate with that chart.

There is a good chance A2-73 will prove to work well and better that the contenders without the serious side effects.

However, there are too many unknown variables and assumptions to calculate anything, not least that so far we don’t actually have in any in study placebo control, only a posthoc comparison to selected natural history patients (on SOC) with a similar baseline as our P2a study patients.

Indicative yes, calculable no.